Electro Optic Systems vote eyed Friday as 34 million potential shares come into play

Electro Optic Systems vote eyed Friday as 34 million potential shares come into play

June 24, 2026

SYDNEY, June 24, 2026, 08:08 AEST

Electro Optic Systems Holdings shareholders are set to vote Friday on whether to issue 5 million strategic shares and approve 21 MARSS performance rights. The performance rights only convert to shares if targets are hit, potentially creating up to 28.94 million shares. In total, these proposed shares would amount to 33.94 million, or about 15.7% of the current 216.7 million shares on issue.

The stock ended at A$9.75, down 4.97% on Tuesday. Volume came in at roughly 6.15 million shares. This story was filed while the Australian cash market was still in pre-open. Normal trading set to begin at about 10 a.m. Sydney.

Generation 5 Holding, or Gen5, agreed to buy 3.75 million shares at A$8, pricing the shares 18% below Tuesday’s close. At the last close of A$9.75, the block is worth A$36.6 million on paper, which is A$6.6 million higher than Gen5’s A$30 million outlay. Another institutional investor with a defence focus is buying 1.25 million shares at A$8, bringing total proceeds from the deal to A$40 million.

MARSS could see a bigger share hit. EOS gave MARSS management shareholders performance rights on May 22, as partial payment for the deal. If fully vested, those rights could convert into 28.94 million shares, about 13.4% of EOS’s current shares.

The earnout can jump by €20 million per €100 million of qualifying third-party MARSS orders, capped at €700 million in orders. Total payout is limited to €140 million. The first 23.53 million shares use a valuation of A$7.40 each for the deal calculation. The next 5.41 million shares get a price based on recent trading before completion. Some of the consideration could be paid in cash. Full share issue would need a big contract win, not just approval of the resolution.

Friday’s vote doesn’t create new rights. Those are already in place. Approval under ASX Listing Rule 7.4 would take them out of EOS’s 15% rolling placement limit, letting the company issue more equity without calling another shareholder vote and opening up more room for financing. If shareholders say no, the rights stay on issue and the placement capacity remains tied up for a year.

Gen5 coming in on the A$8 placement puts more heft behind the capital raise than usual. Last week, EOS said it landed a US$124 million (about A$175 million) Gen5 order for its Slinger counter-drone systems, with shipments set for 2027 and 2028. The order equals 24% of EOS’s A$726 million secured order book announced June 15, and 69% of the midpoint in its A$240 million-A$270 million revenue forecast for 2026 base business. The company isn’t counting any revenue from this order in 2026.

EOS and Gen5 have agreed to set up a 50-50 joint venture in Abu Dhabi under a binding but still conditional deal. Gen5 will put in US$40 million in equity, and EOS will add its existing IP. They want to bring in a US$250 million order for a 200-300 kilowatt laser family inside a year, plus a separate contract of at least US$290 million for multiple 100-kilowatt lasers in nine months. These amounts are targets rather than firm contracted revenue.

EOS Chief Executive Andreas Schwer said buying MARSS will help EOS deliver “complete, AI-enabled counter-drone systems”. MARSS founder Johannes Pinl said the pair offers “genuine end-to-end protection from a single partner”. The deal’s earnout means new orders would back up the plan—and also see more shares go to the sellers. Electro Optic Systems

EOS dropped more than the S&P/ASX 200, which slipped 0.33% Tuesday. DroneShield, also listed in Australia, lost 4.53% to A$2.53. EOS is in its second day as part of the S&P/ASX 200 after being added ahead of Monday’s open.

State Street Group filed on Tuesday that it’s no longer a substantial holder in EOS. The firm has crossed Australia’s 5% disclosure threshold a few times this year, so the filing doesn’t confirm a full exit.

But the deal and JV face tough requirements. The Slinger sale needs export signoff and still has to clear Gen5’s usual terms. The JV isn’t final until it gets board signoff and more agreements. EOS says it might never get those laser orders. EOS gets no ongoing royalty for IP it puts into the JV, and any new IP from a later 200-300 kW development contract will go to the JV. Revenue from MARSS depends on when suppliers deliver and on a pending accounting check.

Votes and proxy forms must be in by 10 a.m. AEST Wednesday. Anyone on the register at 7 p.m. Wednesday can vote. EOS will hold its meeting at 10 a.m. Friday. The board backs all three resolutions.

Mateusz Ługowik

Mateusz Ługowik is a senior markets reporter at Bez-kabli.pl, specializing in technology stocks, artificial intelligence and global financial markets. A graduate of the University of Gdańsk, he previously worked in investment research and market analysis. His coverage helps readers understand the key trends, companies and innovations influencing investors worldwide.

Stock Market Today

  • Pro Medicus steady post-ASX 50 exit with high valuation hurdle
    June 23, 2026, 8:13 PM EDT. Pro Medicus Ltd (ASX: PME) remained steady after its removal from the S&P/ASX 50 index, closing at A$172.93, up 0.08% since Friday. The stock has risen 36% since late May despite the reshuffle. The company's 116x forward fiscal 2026 earnings valuation poses a challenge amid reduced earnings forecasts. Underlying net profit grew 29.7% to A$67.3 million, boosted by a significant unrealised gain on a 4DMedical stake. Pro Medicus secured a five-year, A$16 million renewal with Ohio State University Wexner Medical Center, enhancing recurring revenue prospects. Analysts remain cautious; RBC Capital Markets retains a Sector Perform rating with a A$195 price target. CEO Sam Hupert highlighted a strong revenue outlook from new contracts starting fiscal 2026 and beyond.